CAMBRIDGE, Mass.— Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, has extended its partnership with Takeda Pharmaceutical Co. to diagnose patients with certain genetic disorders.

As part of the agreement, which has been extended until March 2022, Centogene will continue providing access to genetic testing to patients around the world.

Dr. Andrin Oswal, CEO of Centogene, said, “We are pleased to be extending our partnership with Takeda, which will allow us to continue diagnosing and Conentogene originally entered into an agreement with Shire Pharmaceuticals, which is now a subsidiary of Takeda Pharmaceutical Company Limited, to provide diagnostic testing capability to enhance early diagnosis of patients suffering from genetic rare diseases.